RT Journal Article
SR Electronic
T1 Emergence and antibody evasion of BQ and BA.2.75 SARS-CoV-2 sublineages in the face of maturing antibody breadth at the population level
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.06.22283000
DO 10.1101/2022.12.06.22283000
A1 Anouschka Akerman
A1 Vanessa Milogiannakis
A1 Tyra Jean
A1 Camille Esneu
A1 Mariana Ruiz Silva
A1 Timothy Ison
A1 Christina Fitcher
A1 Joseph A Lopez
A1 Deborah Chandra
A1 Zin Naing
A1 Joanna Caguicla
A1 Daiyang Li
A1 Gregory Walker
A1 Supavadee Amatayakul-Chantler
A1 Nathan Roth
A1 Sandro Manni
A1 Thomas Hauser
A1 Thomas Barnes
A1 Anna Condylios
A1 Malinna Yeang
A1 Maureen Wong
A1 Charles S.P. Foster
A1 Sharon Lee
A1 Yang Song
A1 Lijun Mao
A1 Allison Sigmund
A1 Amy Phu
A1 Ann Marie Vande More
A1 Stephanie Hunt
A1 Mark Douglas
A1 Ian Caterson
A1 Kerrie Sandgren
A1 Rowena Bull
A1 Andrew Lloyd
A1 Jamie Triccas
A1 Stuart Tangye
A1 Nathan W Bartlett
A1 David Darley
A1 Gail Matthews
A1 Damien J. Stark
A1 William D. Rawlinson
A1 Fabienne Brilot
A1 Anthony L Cunningham
A1 Anthony D. Kelleher
A1 Anupriya Aggarwal
A1 Stuart G. Turville
YR 2022
UL http://medrxiv.org/content/early/2022/12/07/2022.12.06.22283000.abstract
AB The Omicron era of the COVID-19 pandemic commenced at the beginning of 2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and related sub-lineages. Over the course of 2022, we monitored the potency and breadth of antibody neutralization responses to many emerging variants at two levels: (i) we tracked over 400,000 U.S. plasma donors over time through various vaccine booster roll outs and Omicron waves using sequentially collected IgG pools; (ii) we mapped the antibody response in individuals using blood from strigently curated vaccine and convalescent cohorts. In pooled IgG samples, we observed the maturation of neutralization breadth to Omicron variants over time through continuing vaccine and infection waves. Importantly, in many cases we observed increased antibody breadth to variants that were yet to be in circulation. Determination of viral neutralization at the cohort level supported equivalent coverage across prior and emerging variants with emerging isolates BQ.1.1, XBB.1 and BR.2.1 the most evasive. Further, these emerging variants were resistant to Evusheld, whilst neutralization resistance to Sotrovimab was restricted to BQ.1.1 and this was further supported by lack of antibody binding to this variant. An outgrowth advantage which correlated with better utilization of TMPRSS2 was observed across BQ lineages but not those derived from BA.2.75. We conclude at this current point in time that variants derived from BQ lineages can evade antibodies at levels equivalent to their most evasive BA.2.75 counterparts but sustain an entry phenotype that would promote an additional outgrowth advantage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was primarily supported by Australian Medical Foundation research grants MRF2005760 (ST, GM & WDR), MRF2001684 (ADK and ST) and Medical Research Future Fund Antiviral Development Call grant (WDR), Medical Research Future Fund COVID-19 grant (MRFF2001684, ADK & SGT) and the New South Wales Health COVID-19 Research Grants Round 2 (SGT) and the NSW Vaccine Infection and immunology Collaborative (VIIM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human serum samples were obtained with written informed consent from the participants and have been approved under Ethics review at St Vincents Hospital, Darlinghurst Sydney Australia (ADAPT Cohort) and Ethics review at the Western Sydney Local Health (WSLHD) District (VIIM cohort)(2020/ETH00964; 2020/ETH02068; 2019/ETH03336; 2021/ETH00180; 2021/ETH0042). All primary isolates used herein were obtained from de-identified remnant diagnostic swabs that had completed all diagnostic testing under approval by the New South Wales Chief Health Officer following independent scientific review and as outlined in the ADAPT ethics protocol 2020/ETH00964.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data for generating the figures are available in the online version of the paper in the supplmentary tables. Any other data are available on request